Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fexinidazole - Drugs for Neglected Diseases initiative/Sanofi

Drug Profile

Fexinidazole - Drugs for Neglected Diseases initiative/Sanofi

Alternative Names: Fexinidazole Winthrop; HOE-239

Latest Information Update: 04 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hoechst Pharma
  • Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
  • Class Antiprotozoals; Nitroimidazoles; Skin disorder therapies
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered African trypanosomiasis
  • Phase II Chagas disease
  • Discontinued Visceral leishmaniasis

Most Recent Events

  • 10 Jun 2019 Drugs for Neglected Diseases plans a phase II/III trial for African trypanosomiasis in Malawi and Uganda in June 2019 (NCT03974178)
  • 30 Jan 2019 Registered for African trypanosomiasis (In adolescents, In children, In the elderly, In adults) in Democratic Republic of the Congo (PO)
  • 19 Nov 2018 Discontinued - Phase-II for Visceral leishmaniasis in Sudan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top